Longevity Science · AI Drug Discovery
The drug wasn't built to fight aging. It was built to stop lungs from turning into scar tissue.
Then six independent aging clocks looked at the leftover blood samples, and all six said the same unexpected thing.
Insilico Medicine's AI-designed drug rentosertib was developed to treat idiopathic pulmonary fibrosis, a scarring lung disease. In a secondary analysis of blood samples from 42 trial patients, published in Nature Biotechnology, six independently built proteomic aging clocks — from Insilico, Harvard, Oxford, and Peking University — all detected a shift toward a lower predicted biological age in treated patients, peaking around week four. The clearest reductions ranged from about 2.7 to 3.5 years, with one exploratory clock reading as high as six. A dose mismatch between the drug's best lung effect and its strongest age-reversal signal suggests the two aren't simply the same thing showing up twice. The findings are genuinely interesting and genuinely limited: a 42-person analysis in sick patients, evaluated partly using a clock Insilico itself built, is a hypothesis worth testing further — not proof of an anti-aging drug.
Blood samples collected for an entirely different purpose ended up carrying a signal nobody was specifically looking for.
An AI Drug for Scarred Lungs Accidentally Made Blood Look Younger
Insilico Medicine, a Hong Kong-based company that uses to find and design drugs, built rentosertib for one specific job: treating idiopathic pulmonary fibrosis. This disease slowly turns lung tissue into scar tissue.
The drug's earlier Phase IIa trial, involving 71 patients, met its safety goals and showed a promising dose-dependent trend in lung function. That was the whole story, as far as anyone intended.
Except researchers had also been collecting blood samples throughout the trial, as standard practice. Forty-two of those patients' samples sat available for further analysis.
When the team finally analyzed nearly 3,000 proteins in that blood, they found something nobody had set out looking for. This pattern became the subject of a new paper in Nature Biotechnology.
That paper is the reason a lung disease trial is now part of a conversation about aging biology at all.
What an "Aging Clock" Actually Measures
Blood carries thousands of proteins, and the mix of those proteins shifts in fairly predictable ways as a person gets older.
Different research groups around the world have built their own versions, trained on different populations, using different protein panels, with no coordination between them.
In this study, researchers ran the trial's protein data through six of these clocks: models named ProtAge, two variants of OrganAge, PAC, ipfP3GPT, and PAOPAC, built by Insilico, Harvard, Oxford, and Peking University.
Some were designed to estimate chronological age directly. Others were built to predict health and mortality risk instead. That variety is deliberate — it's what makes agreement across all six meaningful rather than circular.
Why Six Clocks Agreeing Matters More Than One Big Number
No single aging clock is perfect. Any one of them could be picking up a quirk of its own training data rather than something real about biology.
That's exactly why the researchers didn't rely on just one. Nobel laureate Michael Levitt, who reviewed the findings, has pointed out that what makes this result notable isn't the size of any single effect.
It's that six models sharing neither their underlying features nor their training data all pointed in the same direction — toward a lower predicted biological age in treated patients.
Any one clock being wrong is entirely plausible. Six independently built clocks being wrong in exactly the same direction is a much harder coincidence to explain away.
That agreement, more than any specific number of years, is the actual finding worth paying attention to here.
The Trial Nobody Designed to Find This
It's worth being precise about the scale of what's actually being discussed, because that context shapes how seriously to take any part of this.
The analysis covered 42 participants with an average age of 67, measuring reactions across nearly 3,000 blood proteins at baseline and at weeks two, four, and twelve.
All six clocks detected a shift toward lower predicted biological age in the treated group. The placebo group showed little change, and some clocks even suggested a slight increase in biological age among those patients.
The clearest results appeared around week four. In the 60-milligram once-daily group, clocks built to estimate chronological age showed reductions ranging from roughly 2.7 to 3.5 years, with one exploratory clock reading as high as six years.
Notably, that apparent age-reversal effect plateaued after week four rather than continuing to grow, even though many of the underlying protein changes persisted through the full twelve-week study.
The Detail That Undercuts the Obvious Objection
There's an obvious skeptical read here: these are sick patients whose lungs improved, so of course their blood looks healthier — maybe the clocks are just detecting "less ill" and mislabeling it as "younger."
That's a fair objection, and the data pushes back on it in a specific way.
| Outcome | Best-Performing Dose |
|---|---|
| Lung function improvement | 60 mg once daily |
| Strongest aging-clock signal | 30 mg twice daily |
The dose that helped the lungs most, 60 milligrams once a day, was not the dose that produced the strongest aging-clock signal, which was 30 milligrams taken twice a day.
If the aging effect were simply a side effect of healthier lungs, those two outcomes should track together on the same dose. They don't, which suggests something else, at least partly independent of the lung disease, is happening underneath.
The researchers also compared treated patients' protein profiles against more than 55,000 samples from the UK Biobank and identified what they describe as a senomorphic mechanism — the drug appears to suppress drivers of cellular senescence, rather than simply reflecting a healthier lung.
The Conflict of Interest Worth Knowing About
There's a detail that responsible coverage of this study needs to include plainly, rather than burying it.
None of that makes the result automatically wrong. But a company partly measuring its own drug with its own measuring instrument is a fact any reader deserves to know before weighing the claim.
To its credit, Insilico has deposited its proteomic data with the China National Center for Bioinformation and published its analysis pipeline as open-source software — meaningfully more transparency than many industry-funded studies offer.
That openness means the claim is checkable by researchers who didn't write the original paper, which is exactly the kind of scrutiny a result like this should invite and withstand.
From a Lung Drug to a Longevity Factory
The part of this story that's genuinely about AI, rather than pharmacology alone, is how rentosertib got made in the first place.
Insilico's target-discovery platform identified TNIK, a gene linked to six recognized hallmarks of aging, as relevant to both aging biology and pulmonary fibrosis — a dual-purpose target that gave the drug a shot at both conditions from the start.
A separate generative chemistry system then designed a molecule shaped to fit that target. The whole path from target identification to preclinical candidate took roughly 18 months — a stage that routinely takes years in conventional drug development.
Rentosertib is now in Phase III trials in China for the lung disease, the stage before potential approval. Eli Lilly has invested in Insilico to help push AI co-developed drugs toward market.
Insilico's CEO says the company has generated at least 28 drug candidates using this same pipeline as of earlier this year, with several already in clinical trials — suggesting this isn't a one-off lucky molecule, but a repeatable process.
Manohar Insight
What I find genuinely compelling about this story is exactly what the researchers themselves are careful not to oversell: the direction of the signal, not the size of it.
A 42-person analysis, in sick patients, with one of the four evaluating groups being the drug's own maker, is not proof of an anti-aging breakthrough. It shouldn't be reported that way, and to its credit, Insilico's own announcement is carefully hedged.
But the dose mismatch is a genuinely hard detail to wave away. Coincidences don't usually show up as two cleanly separated doses producing two cleanly separated best outcomes.
The transparency here also deserves real credit: open data, open analysis code, and a plainly stated conflict of interest. That's a higher bar than most industry-funded longevity claims clear.
The next test everyone actually needs is the obvious one: healthy volunteers, not sick lungs. Until that happens, this stays a hypothesis with real supporting evidence, not a finding.
I'd also flag the bigger pattern here over the single result: an 18-month path from target to candidate, and 28 more candidates already in the pipeline, matters more long-term than whether this one molecule pans out.
The real story isn't that a drug reversed aging. It's that a leftover blood sample, analyzed properly, found something nobody was even looking for — and that's usually how genuine discoveries actually happen.
Join the Signal
If a company partly evaluates its own drug using a measuring tool it built itself, how much should that shape how you read an otherwise promising result? Share your take in the comments.
Discussion